BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30533206)

  • 1. Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis.
    Henriksen DP; Bodtger U; Sidenius K; Maltbaek N; Pedersen L; Madsen H; Andersson EA; Norgaard O; Madsen LK; Chawes BL
    Eur Clin Respir J; 2018; 5(1):1536097. PubMed ID: 30533206
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-IL-5 therapies for asthma.
    Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-IL5 therapies for asthma.
    Farne HA; Wilson A; Powell C; Bax L; Milan SJ
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the risk of infection events in patients with asthma receiving
    Giossi R; Pani A; Schroeder J; Scaglione F
    Heliyon; 2024 Jan; 10(1):e23725. PubMed ID: 38268596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
    Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
    J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
    Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
    Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis.
    Yan K; Balijepalli C; Sharma R; Barakat S; Sun SX; Falcao S; Druyts E; FitzGerald JM
    Immunotherapy; 2019 Dec; 11(17):1491-1505. PubMed ID: 31686556
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
    Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
    Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma].
    Zyryanov SK; Avdeev SN; Ivanov DA; Zhuravleva MV; Kniajeskaia NP; Matveev NV; Nenasheva NA; Fomina DS; Frolov MI
    Ter Arkh; 2020 Dec; 92(12):172-179. PubMed ID: 33720591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials.
    Cabon Y; Molinari N; Marin G; Vachier I; Gamez AS; Chanez P; Bourdin A
    Clin Exp Allergy; 2017 Jan; 47(1):129-138. PubMed ID: 27859832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.
    Edris A; De Feyter S; Maes T; Joos G; Lahousse L
    Respir Res; 2019 Aug; 20(1):179. PubMed ID: 31395084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mepolizumab versus placebo for asthma.
    Powell C; Milan SJ; Dwan K; Bax L; Walters N
    Cochrane Database Syst Rev; 2015 Jul; (7):CD010834. PubMed ID: 26214266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
    Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
    Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis.
    Phinyo P; Krikeerati T; Vichara-Anont I; Thongngarm T
    J Allergy Clin Immunol Pract; 2024 Feb; 12(2):409-420. PubMed ID: 37972921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
    Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.
    Charles D; Shanley J; Temple SN; Rattu A; Khaleva E; Roberts G
    Clin Exp Allergy; 2022 May; 52(5):616-627. PubMed ID: 35174566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.
    Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
    Clin Exp Allergy; 2020 Apr; 50(4):442-452. PubMed ID: 31943429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
    Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.